SCHEMBL2208069

SCHEMBL2208069

O=C(O)CSCc1cccc(I)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.60
HTT P42858 1/20 0.46
RAB9A P51151 3/20 0.44
POLB P06746 2/20 0.44
CYP2C19 P33261 3/20 0.43
KDM4E B2RXH2 1/20 0.43
MMP12 P39900 1/20 0.42
MMP13 P45452 1/20 0.42
CYP2D6 P10635 2/20 0.41
THPO P40225 1/20 0.41
HIF1A Q16665 1/20 0.41
MAOB P27338 1/20 0.41
IDO1 P14902 2/20 0.41
ALDH1A1 P00352 1/20 0.41
NPC1 O15118 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
PMP22 Q01453 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2210848 0.86 KMT2A (0.50) CYP1A2RAB9APOLBCYP2C19CYP2D6
SCHEMBL2210286 0.82 CYP1A2 (0.52) CYP1A2HTTRAB9APOLBCYP2C19
SCHEMBL3905722 0.81 CYP1A2 (0.62) CYP1A2HTTRAB9APOLBCYP2C19
SCHEMBL22288725 0.80 IDO1 (0.47) CYP1A2RAB9ACYP2C19CYP2D6THPO
SCHEMBL10419640 0.79 CYP1A2 (0.65) CYP1A2HTTCYP2C19KDM4ECYP2D6
SCHEMBL8470768 0.79 CYP1A2 (0.60) CYP1A2CYP2C19KDM4ECYP2D6IDO1
SCHEMBL3910561 0.79 CYP1A2 (0.60) CYP1A2HTTRAB9APOLBCYP2C19
SCHEMBL1635769 0.79 CYP1A2 (0.60) CYP1A2HTTRAB9APOLBCYP2C19
SCHEMBL15083077 0.79 CYP1A2 (0.65) CYP1A2HTTRAB9APOLBCYP2C19
SCHEMBL30050703 0.79 CYP1A2 (0.60) CYP1A2HTTRAB9APOLBCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1737815-B1 THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES CEPHALON INC (US) 2016-12-21 EP disclosed
US-7981907-B2 Thio-substituted biarylmethanesulfinyl derivatives CEPHALON, INC. (US) 2011-07-19 US disclosed
US-20090062284-A1 Thio-Substituted Biarylmethanesulfinyl Derivatives CEPHALON, INC. (US) 2009-03-05 US disclosed
US-7449481-B2 e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue CEPHALON, INC. (US) 2008-11-11 US disclosed
EP-1737815-A1 THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES CEPHALON, INC. (US) 2007-01-03 EP disclosed
US-20050245747-A1 e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue CEPHALON, INC. (US) 2005-11-03 US disclosed
WO-2005100308-A1 THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES CEPHALON, INC. (US) 2005-10-27 WO disclosed
EP-1586559-A1 Biaryl-methanethio-, -sulphinyl- and sulphonyl derivatives CEPHALON, INC. (US) 2005-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062284-A1 Thio-Substituted Biarylmethanesulfinyl Derivatives AANAT, SNCA, NAT1 CYP1A2 76/4885HTT 373/4885RAB9A 2634/4885
US-20050245747-A1 e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue TPH2, TPH1, AANAT CYP1A2 194/4885HTT 235/4885RAB9A 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.